华仁药业：盐酸异丙肾上腺素原料药获批上市

Core Viewpoint - Huanren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of "Isoproterenol Hydrochloride" [1] Group 1: Company Developments - The approval pertains to Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist that strongly stimulates both β1 and β2 receptors [1] - Isoproterenol Hydrochloride is clinically used for treating conditions such as cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]